Your session is about to expire
← Back to Search
Machine Perfusion System
Machine Perfusion for Liver Transplant (PILOT™_CA Trial)
N/A
Recruiting
Research Sponsored by Organ Recovery Systems, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights
PILOT™_CA Trial Summary
This trial will provide safety data to help evaluate a new medical treatment.
Who is the study for?
This trial is for adults over 18 who need a new liver and are on the UNOS waiting list. They must be first-time transplant recipients, not have HIV, severe infections, or acute liver failure. Pregnant individuals or those getting multiple organ transplants can't participate.Check my eligibility
What is being tested?
The study tests the LifePort Liver Transporter System's performance in preserving livers for transplant through Hypothermic Machine Perfusion—a way to keep organs cold while supplying them with nutrients and oxygen before surgery.See study design
What are the potential side effects?
Since this trial focuses on a machine perfusion system rather than a drug, traditional side effects aren't applicable. However, there may be risks related to how well the preserved liver functions after transplantation.
PILOT™_CA Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 7 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Transplantation, Homologous
PILOT™_CA Trial Design
1Treatment groups
Experimental Treatment
Group I: Hypothermic Machine PerfusionExperimental Treatment1 Intervention
Hypothermic Machine Perfusion with Organ Recovery Systems LifePort Liver Transporter system
Find a Location
Who is running the clinical trial?
Organ Recovery Systems, Inc.Lead Sponsor
1 Previous Clinical Trials
142 Total Patients Enrolled
Stan HarrisStudy DirectorOrgan Recovery Systems
1 Previous Clinical Trials
142 Total Patients Enrolled
Matthew CopithorneStudy ChairOrgan Recovery Systems
1 Previous Clinical Trials
142 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My blood type does not match the donor liver's blood type.I am experiencing sudden severe liver failure.I am on the UNOS waiting list for a liver transplant.I have received a liver transplant for the first time.I have received multiple organ transplants.I am currently suffering from a severe infection.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Hypothermic Machine Perfusion
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any unfilled opportunities for participants in this research?
"Affirmative. The clinicaltrials.gov website reveals that this test, which was published on September 19th 2022, is actively recruiting participants. Approximately 120 individuals must be sourced from 2 different medical centres."
Answered by AI
What is the upper capacity of this clinical trial?
"Affirmative. According to the information from clinicaltrials.gov, this trial is presently seeking volunteers for participation and was initially posted on September 19th 2022. There are a total of 120 participants required between two sites with the latest update being made October 10th 2022."
Answered by AI
Share this study with friends
Copy Link
Messenger